Biochemical Outcome Following External Beam Radiation Therapy With or Without Androgen Suppression Therapy for Clinically Localized Prostate Cancer

Open Access
Publisher Website
Google Scholar
Abstract
Treatment selection for men with clinically localized prostate cancer should be based on the results of carefully designed and well-conducted prospective randomized trials. Two randomized trials, one performed by the Radiation Therapy Oncology Group (RTOG)1 and the other by the European Organization for Research in the Therapy of Cancer (EORTC)2 have documented a benefit in cancer-specific survival for patients with locally advanced (T3, T4) prostate cancer who received a combination of external beam radiation therapy (RT) and short-(4 months) or long-term (3 years) androgen suppression therapy (AST), respectively, compared with RT alone. For men with clinically localized prostate cancer, 2 trials, one performed by the RTOG (RT with or without 4 months of AST) and the other by the Dana Farber Cancer Institute (RT with or without 6 months of AST), are expected to reach their target accruals during 2000.